LONDON, UK / ACCESSWIRE / August 1, 2024 / The Company announces that on 31 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / July 31, 2024 / Ecora Resources PLC (LSE:ECOR)(TSX:ECOR) has received notification of the following transactions by Kevin Flynn, Chief Financial Officer, and Marc Bishop Lafleche, Chief Executive Officer. On 26 July 2024, Mr.
LONDON, UNITED KINGDOM / ACCESSWIRE / July 31, 2024 / The Company announces that on 30 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
Flutter Entertainment to Report Second Quarter 2024 Financial Results and Host a Conference Call on August 13, 2024 DUBLIN, IRELAND / ACCESSWIRE / July 30, 2024 / Flutter Entertainment plc ("Flutter") (NYSE:FLUT)(LSE:FLTR), the leading online sports betting and iGaming operator, today announced that it will release its second quarter 2024 financial results after market close on Tuesday, August 13, 2024 at 16:05 ET (21:05 BST). The earnings release and supplementary materials will be available through the "Investors" section of the Flutter website at www.flutter.com.
LONDON, UNITED KINGDOM / ACCESSWIRE / July 30, 2024 / Argo Blockchain plc, (LSE:ARB)(NASDAQ:ARBK), is pleased to announce that it has entered into a securities purchase agreement for a private placement of its ordinary shares ("Ordinary Shares") and accompanying warrants to purchase Ordinary Shares to an institutional investor for gross proceeds of approximately GBP £6.5 million (the "Private Placement"). Pursuant to the Private Placement, the Company will issue 57,800,000 Ordinary Shares (the "Placement Shares") at a purchase price of GBP £0.1125 per Ordinary Share along with warrants to purchase up to 57,800,000 Ordinary Shares (the "Warrants").
LONDON, UNITED KINGDOM / ACCESSWIRE / July 30, 2024 / The Company announces that on 29 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
InterContinental Hotels Group PLC (the Company) Purchase of own shares LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / The Company announces that on 26 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
Presentation at Macrophage-Directed Therapies Summit LONDON, UNITED KINGDOM / ACCESSWIRE / July 29, 2024 / Hemogenyx Pharmaceuticals plc ("Hemogenyx Pharmaceuticals" or the "Company")(LSE:HEMO), the clinical-stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to announce its participation in the 6th Macrophage-Directed Therapies Summit ("Summit"), which will be held on October 1-3, 2024, in Boston, MA. The Company will present its work on its proprietary Chimeric Bait Receptor ("CBR") platform.
LONDON, UK / ACCESSWIRE / July 26, 2024 / The Company announces that on 25 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UK / ACCESSWIRE / July 26, 2024 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF) 'Poolbeg' or the 'Company'), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it is voluntarily delisting its ordinary shares ("Ordinary Shares") from trading on the OTCQB Market due to low trading volume and the associated administrative requirements. The Company's last day of trading on the OTCQB Market will be Monday 29 July 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / July 25, 2024 / The Company announces that on 24 July 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / July 24, 2024 / Ecora Resources PLC (LSE/TSX: ECOR) issues the following trading update for the period 1 April to 30 June 2024. Ecora is the leading royalty company focused on supporting the supply of industrial commodities essential to creating a sustainable future.